Author: healthprofessionalradio

Dr. James Tursi, MD, Chief Scientific Officer of Ferring Pharmaceuticals discusses developments in microbiome-based therapeutics for the treatment of recurrent C. difficile (rCDI) infection. The current standard of care treatment for rCDI is currently antibiotics. While they are important, they do not restore the underlying health of the gut microbiome, nor can they stop C. diff​icile​ spores from growing back. He talks about what their late stage pivotal Phase 3 clinical trial results showed regarding mitigating recurrent C. difficile infection.​ ​The ​gut ​microbiome is an emerging area where biotherapeutics are being developed to address certain diseases and conditions.​ 

Returning guest, Dr. Kaveh Safavi, Global Health Lead of Accenture Health, discusses the findings from their 2021 Digital Health Tech Vision report that surveyed 399 healthcare executives across six countries to better understand their view of the impact technology is having on the healthcare industry and what this means for the future.  

Girish Navani, CEO and Cofounder of eClinicalWorks, a leader in healthcare IT solutions discusses PRISMA, the healthcare industry’s first health information search engine that leverages a “one patient, one record” approach for fast and accurate decision-making that can be lifesaving. This platform helps to better know patients and provide more effective clinical care and can even cut patient wait times from approximately 30 minutes to 10 minutes. 

Returning guest, Dr. Larry Edwards, ​MD, MACP, MACR, rheumatologist and Chairman of the Gout Education Society discusses managing gout during the summer, with travel and get togethers, and how HCPs can prepare their patients to manage proper medications and lifestyle habits during this time. 

Returning guest, Dr. Jeremy Levin, Chairman and CEO of Ovid Therapeutics, Inc., and former chairman of the global Biotechnology Innovation Organization (BIO) discusses the new COVID variant Delta-Plus, a virus that mutated from the highly infective Delta version, and why vaccinations are so crucial.

Dr. Ryan Mathis, MD, Vice President of Commercial Strategy at PolarityTE discusses SkinTE™ an innovative alternative for the treatment of chronic wounds, like diabetic foot ulcers (DFUs). He talks about the science behind SkinTE™, how it’s made of a patient’s own full-thickness skin, which retains the endogenous regenerative cellular populations found throughout his/her skin within multicellular segments. He also shares information from real-world studies of difficult to treat wounds. SkinTE™ is on track for IND submission in the second half of 2021. 

Returning guest, Dr. Bruce Sands, M.D., M.S., Chief of the Dr. Henry D. Janowitz Division of Gastroenterology at Mount Sinai Hospital and the Dr. Burrill B. Crohn Professor of Medicine (Gastroenterology), at the Icahn Institute for Medicine at Mount Sinai discusses new data presented at the 16th Congress of European Crohn’s and Colitis Organisation (ECCO) from a trial evaluating biologic induction and maintenance therapy for moderately to severely active ulcerative colitis.

Leon Lerman, CEO of Cynerio, the leading provider of Healthcare IoT cybersecurity and asset management solutions discusses the biggest security challenges for healthcare in a post-COVID environment, why health systems should move to the Zero Trust model to secure their systems and devices, and whether governing bodies should provide cybersecurity requirements for healthcare.  

Returning guest, Dr. Gregg Sylvester, Chief Medical Officer at Seqirus, a global leader in influenza prevention, discusses data from a first-of-its-kind co-administration study conducted by Novavax of the SARS-CoV-2 vaccine candidate (Novavax, NVX-CoV2373) and an approved influenza vaccine (Seqirus, Flucelvax Quadrivalent and Fluad).  He talks about the potential advantages for patients and physicians to co-administer an approved COVID-19 and influenza vaccine, how these findings may impact proposed immunization scheduling for varying age groups and alter CDC recommendations, and the importance of these findings as we approach a critical 2021/22 influenza season while many populations are still in need of a primary COVID-19 vaccine series or booster dose. 

Mike Lipps, CEO of Intelerad, a global leader in medical image management discusses why hospitals and health systems need fewer integrations to be able to truly manage their data and images and how a greater focus on data analytics can improve collaborative care. He also talks about the company’s recent growth and momentum that furthers the company’s mission to provide customers with the most comprehensive enterprise imaging platform in the industry.